Company Cerevel Therapeutics Holdings, Inc.

Equities

CERE

US15678U1280

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-15 pm EDT 5-day change 1st Jan Change
41.7 USD -0.36% Intraday chart for Cerevel Therapeutics Holdings, Inc. -1.21% -1.65%

Business Summary

Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.

Number of employees: 334

Managers

Managers TitleAgeSince
Chief Executive Officer 55 23-06-11
Director of Finance/CFO 43 23-05-14
Chairman 63 18-11-30
Chief Tech/Sci/R&D Officer 63 18-12-31
Chief Tech/Sci/R&D Officer 55 19-04-30
53 -
Investor Relations Contact - -
General Counsel 40 21-05-23
Comptroller/Controller/Auditor 51 19-08-31
Corporate Officer/Principal 50 23-06-19

Members of the board

Members of the board TitleAgeSince
Director/Board Member 63 19-05-31
Director/Board Member 66 20-12-03
Director/Board Member 67 21-01-19
Director/Board Member 65 18-08-31
Director/Board Member 66 18-11-30
Chairman 63 18-11-30
Chief Executive Officer 55 23-06-11
Director/Board Member 51 18-08-31
Director/Board Member 55 22-06-13
Director/Board Member 55 21-01-19

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 181,576,482 76,702,134 ( 42.24 %) 0 42.24 %

Shareholders

NameEquities%Valuation
Bain Capital Private Equity LP
36.17 %
65,679,781 36.17 % 2 776 M $
27,349,211 15.06 % 1 156 M $
Perceptive Advisors LLC
6.039 %
10,965,193 6.039 % 463 M $
Perceptive Advisors LLC
5.945 %
10,794,876 5.945 % 456 M $
Fidelity Management & Research Co. LLC
5.338 %
9,691,851 5.338 % 410 M $
Avoro Capital Advisor LLC
4.161 %
7,555,555 4.161 % 319 M $
Vanguard Fiduciary Trust Co.
4.062 %
7,374,970 4.062 % 312 M $
BlackRock Advisors LLC
3.151 %
5,721,190 3.151 % 242 M $
2,851,819 1.571 % 121 M $
Fidelity Investments Canada ULC
1.523 %
2,766,000 1.523 % 117 M $

Company contact information

Cerevel Therapeutics Holdings, Inc.

222 Jacobs Street Suite 200

02141, Cambridge

+844 304 2048

http://www.cerevel.com
address Cerevel Therapeutics Holdings, Inc.(CERE)
  1. Stock Market
  2. Equities
  3. CERE Stock
  4. Company Cerevel Therapeutics Holdings, Inc.